Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.65 USD
Change Today -0.04 / -1.08%
Volume 30.0K
As of 11:29 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

psivida corp (PSDV) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/3/14 - $4.94
52 Week Low
07/8/15 - $3.23
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PSIVIDA CORP (PSDV)

psivida corp (PSDV) Related Businessweek News

No Related Businessweek News Found

psivida corp (PSDV) Details

pSivida Corp. develops products to deliver drugs and biologics in the United States and the United Kingdom. The company develops its products based on its Durasert and Tethadur drug delivery technologies focusing on the treatment of chronic diseases of the back of the eye. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company also provides Medidur, an injectable, sustained-release micro-insert designed to treat non-infectious uveitis affecting the posterior segment of the eye, which is in Phase III clinical trial.It has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; Enigma Therapeutics Limited; and Intrinsiq Materials Cayman Limited. The company was founded in 1987 and is headquartered in Watertown, Massachusetts.

24 Employees
Last Reported Date: 09/11/14
Founded in 1987

psivida corp (PSDV) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $708.6K
Principal Financial & Accounting Officer and ...
Total Annual Compensation: $316.0K
Vice President of Corporate Affairs, General ...
Total Annual Compensation: $433.5K
Compensation as of Fiscal Year 2014.

psivida corp (PSDV) Key Developments

pSivida Corp. Announces Top-Line Results from Investigator-Sponsored Phase II Study of Medidur for Uveitis

pSivida Corp. announced that top line results from an investigator-sponsored, Phase II study of pSivida’s Medidur for uveitis will be presented at the 33rd Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) meeting to be held July 10 to 14 in Vienna, Austria. Dr. Glenn J. Jaffe, Robert Machemer Professor of Ophthalmology at Duke University School of Medicine in Durham, NC, who is conducting this study, will make the presentation. He also serves as principal investigator in pSivida’s first pivotal Phase III trial for Medidur for posterior uveitis, which is currently underway.

pSivida Corp. Reports Positive IOP Safety Data in Phase III Trial of Medidur™ for Posterior Uveitis

pSivida Corp. announced positive safety data from its ongoing assessment of masked safety data from its first Phase III clinical trial of Medidur for posterior uveitis, a blinding eye disease. At three months, only 4% more study eyes (2/3 of which received Medidur) experienced elevated intraocular pressure (IOP) than the fellow non-study eyes (none of which received Medidur). Initial IOP elevation is an indication of the likelihood of subsequent clinically significant IOP increases. The minimal difference observed in elevated IOP in the assessment suggests highly favorable results for a key safety measure of the trial, the number of eyes that develop clinically significant increases in IOP within 12 months of receiving Medidur relative to control eyes. The assessment of masked data compared the elevation of IOP over 21mmHg at three months study eyes and fellow eyes for the 105 out of 129 enrolled subjects with at least three month follow-up data. On the basis of this ongoing assessmentof masked study safety data, now believe the final IOP results in the Medidur trial could be even better than those shown in the ILUVIEN and Retisert Phase III trials. At 36 months, 24% more patients treated with ILUVIEN and 45% more patients treated with Retisert required medication for elevated IOP than controls in their Phase III trials. The company expects top line results from this first Phase III trial of Medidur to be available in second quarter of 2016, and with favorable results from this and second trial, which has just been initiated, intend to file for U.S. approval in the first half of 2017.

pSivida Announces Two Tech Evaluation Agreements with Global Pharmaceutical Company

pSivida Corp. announced that it has signed two funded technology evaluation agreements with global pharmaceutical company. The agreements will each evaluate the use of pSivida’s Durasert™ technology to deliver a specific compound to treat a significant ophthalmic disease.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSDV:US $3.65 USD -0.04

PSDV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Regeneron Pharmaceuticals Inc $503.22 USD +6.79
View Industry Companies

Industry Analysis


Industry Average

Valuation PSDV Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PSIVIDA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at